Development and characterization of a first-in-class small molecule inhibitor of PELP1

被引：0
|
作者：
Altwegg, Kristin A. [1 ]
Viswanadhapalli, Suryavathi [1 ]
Mann, Monica [1 ]
Pratap, Uday P. [1 ]
Li, Mengxing [1 ]
Liu, Junhao [1 ]
Luo, Yiliao [1 ]
Sareddy, Gangadhara R. [1 ]
Vankayalapati, Hariprasad [2 ]
Vadlamudi, Ratna K. [1 ]
机构：
[1] UT Hlth San Antonio, San Antonio, TX USA
[2] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P3-10-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-10-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Synergistic effects of RPT1G, a first-in-class small molecule NAMPT inhibitor, with venetoclax and olaparib in hematological malignancies
    Crimmins, Gregory
    Wu, Min
    Roushar, Francis
    Bhurruth-Alcor, Yushma
    Jarvela, Timothy
    Digel, James
    Robb, Caroline
    Moghaddam-Taaheri, Parisa
    De Jesus-Diaz, Dennise
    McCormick, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA
    Gu, Long
    Lingeman, Robert
    Yakushijin, Fumiko
    Sun, Emily
    Cui, Qi
    Chao, Jianfei
    Hu, Weidong
    Li, Hongzhi
    Hickey, Robert J.
    Stark, Jeremy M.
    Yuan, Yate-Ching
    Chen, Yuan
    Vonderfecht, Steven L.
    Synold, Timothy W.
    Shi, Yanhong
    Reckamp, Karen L.
    Horne, David
    Malkas, Linda H.
    CLINICAL CANCER RESEARCH, 2018, 24 (23) : 6053 - 6065
  • [23] DEVELOPMENT OF A NOVEL FIRST-IN-CLASS ORAL INHIBITOR OF THE NOTCH PATHWAY
    Lehal, R.
    Frismantas, V.
    Reinmuller, V.
    Turcatti, G.
    Bourquin, J. P.
    Radtke, F.
    HAEMATOLOGICA, 2016, 101 : 29 - 29
  • [24] RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
    Oronsky, Bryan
    Carter, Corey A.
    Caroen, Scott
    Scribner, Curtis
    Oronsky, Arnold
    Reid, Tony R.
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [25] First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators
    Abdel-Rahman, Somaya A.
    Swiderek, Katarzyna
    Gabr, Moustafa T.
    RSC MEDICINAL CHEMISTRY, 2023, 14 (09): : 1767 - 1777
  • [26] First-in-class Small-molecule Inhibitor of Nox4 Promotes Reversal of Established Pulmonary Fibrosis
    Hecker, L.
    Kato, K.
    Papageorgiou, J.
    Gokhale, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [27] First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
    Karimaa, Mari
    Riikonen, Reetta
    Kettunen, Henna
    Taavitsainen, Paivi
    Ramela, Meri
    Chrusciel, Marcin
    Karlsson, Stefan
    Rummakko, Petteri
    Simola, Outi
    Wohlfahrt, Gerd
    Hakulinen, Pasi
    Vuorela, Annamari
    Joensuu, Heikki
    Utriainen, Tapio
    Fizazi, Karim
    Oksala, Riikka
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (12) : 1765 - 1776
  • [28] An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
    Ushijima, Miho
    Shiota, Masaki
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Eto, Masatoshi
    CANCER SCIENCE, 2022, 113 (05) : 1731 - 1738
  • [29] AN ORAL FIRST-IN-CLASS SMALL MOLECULE RSK INHIBITOR SUPPRESSES AR VARIANTS AND TUMOR GROWTH IN PROSTATE CANCER
    Shiota, Masaki
    Ushijima, Miho
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Eto, Masatoshi
    JOURNAL OF UROLOGY, 2022, 207 (05): : E98 - E99
  • [30] The role of PELP1 inhibitor SMIP34 in the treatment of endometrial cancer
    Yang, Xue
    Liu, Zexuan
    Tang, Weiwei
    Pratap, Uday P.
    Collier, Alexia B.
    Alwegg, Kristin A.
    Spencer, Nicole
    Li, Xiaonan
    Valente, Philip T.
    Kost, Edward R.
    Viswanadhapalli, Suryavathi
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2023, 83 (07)
12345